Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event

Area of Science:

• Hematology
• Oncology
• Cardiovascular Medicine

Background:

• Tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes for chronic myeloid leukemia (CML) patients, nearing life expectancy of healthy individuals.
• Despite improved survival, CML patients on TKIs face a higher risk of adverse events, notably cardiovascular events.
• Clonal hematopoiesis (CH) is recognized as an independent risk factor for cardiovascular events, linked to inflammation and somatic mutations.

Purpose of the Study:

• To investigate the prevalence of clonal hematopoiesis in chronic myeloid leukemia patients who experience cardiovascular events while undergoing TKI therapy.
• To explore the relationship between CH, inflammation, and cardiovascular complications in the context of CML treatment.

Main Methods:

• Retrospective analysis of CML patients treated with TKIs.
• Assessment for the presence of clonal hematopoiesis.
• Evaluation of cardiovascular event occurrence.
• Correlation analysis between CH, TKI therapy, and cardiovascular events.

Main Results:

• A significant proportion of CML patients developing cardiovascular events under TKI therapy exhibited clonal hematopoiesis.
• Findings suggest a potential link between CH and the increased cardiovascular risk observed in this patient population.
• The interplay between somatic mutations in CH and chronic inflammation may exacerbate cardiovascular risk.

Conclusions:

• Clonal hematopoiesis is a relevant factor to consider in the long-term management of CML patients, particularly regarding cardiovascular health.
• Further research is warranted to elucidate the precise mechanisms linking CH, TKI therapy, and cardiovascular events.
• Monitoring for CH may aid in stratifying cardiovascular risk in CML patients undergoing TKI treatment.